Provided by Tiger Fintech (Singapore) Pte. Ltd.

MediciNova

1.50
-0.0100-0.66%
Volume:2.22K
Turnover:3.40K
Market Cap:73.57M
PE:-6.66
High:1.55
Open:1.51
Low:1.50
Close:1.51
Loading ...

MediciNova Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
4 hours ago

MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025

GlobeNewswire
·
15 Apr

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
09 Apr

MediciNova says first patient enrolled in EAP trial to evaluate MN-166

TIPRANKS
·
09 Apr

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

GlobeNewswire
·
09 Apr

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
14 Mar

MediciNova Is Maintained at Buy by D. Boral Capital

Dow Jones
·
21 Feb

MediciNova Inc expected to post a loss of 5 cents a share - Earnings Preview

Reuters
·
12 Feb

MNOV: Encouraging Interim Analysis for Phase 2b/3 ALS Trial…

Zacks Small Cap Research
·
09 Dec 2024

BRIEF-Medicinova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of Mn-166 (Ibudilast)

Reuters
·
06 Dec 2024

Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd

THOMSON REUTERS
·
06 Dec 2024

MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data

THOMSON REUTERS
·
06 Dec 2024

MediciNova Inc - Expects to Complete Patient Assignments by June 2025 With Trial Results Expected in 2026

THOMSON REUTERS
·
06 Dec 2024

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

GlobeNewswire
·
06 Dec 2024

MediciNova Initiated at Buy by D. Boral Capital

Dow Jones
·
02 Dec 2024

MNOV: Monetary Damages Due Following Sanofi/Novartis Patent Dispute Settlement…

Zacks Small Cap Research
·
25 Nov 2024

MediciNova provides update in letter to stockholders

TIPRANKS
·
19 Nov 2024

Medicinova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

THOMSON REUTERS
·
19 Nov 2024

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

GlobeNewswire
·
19 Nov 2024

MediciNova granted Notice of Allowance for MN-001 patent by USPTO

TIPRANKS
·
15 Nov 2024